Gaurav Jadon
Research Subjects
Gaurav Jadon has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amit Agrawal
Department of Pediatrics, Gandhi Medical College, Bhopal, India
3 shared publications - Dalwinder Janjua
Al Jalila Children's Specialty Hospital, Dubai, United Arab Emirates
2 shared publications Japna Singh
International Modern Hospital, Dubai, United Arab Emirates
1 shared publication- Pankaj Soni
Department of Neonatology, Thumbay University Hospital, Ajman, UAE
1 shared publication - Roshan Chanchlani
Department of Pediatric Surgery, All India Institute of Medical Sciences, Bhopal, MP, India
1 shared publication - Shweta Sharma
Department of Pediatrics, Gandhi Medical College, Bhopal, MP, India
1 shared publication
Latest Publications
- Open Access
- 15 December 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (12) , 963-970
Exploring nutritional screening tools for hospitalized children: a narrative review
Malnutrition is common among hospitalized children, especially those who are critically ill. Routine measures, such as anthropometric measurements, body composition, and nutritional assessment, comprise the basics of monitoring. This review discusses the adequacy of nutritional screening tools (NSTs) such as the SGNA (Subjective Global Nutritional Assessment), PYMS (Pediatric Yorkhill Malnutrition Score), STAMP (Screening Tool for the Assessment of Malnutrition in Paediatrics), and STRONGkids (Screening Tool for Risk of Nutritional Status and Growth). This review included recently published reports supporting the validation and implementation of NSTs in pediatric populations. A child's nutritional status during hospitalization is of great importance for their recovery, while the implementation of screening tools enhances their clinical outcomes. Current tools have varying sensitivities and specificities, and no single tool can be recommended for all groups of hospitalized children. A combination of tools or adaptation of existing tools with validation in different contexts might be ideal. Further studies are required to develop more robust and comprehensive screening tools.
- 15 December 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (12) , 963-970
Open AccessExploring nutritional screening tools for hospitalized children: a narrative review
Malnutrition is common among hospitalized children, especially those who are critically ill. Routine measures, such as anthropometric measurements, body composition, and nutritional assessment, comprise the basics of monitoring. This review discusses the adequacy of nutritional screening tools (NSTs) such as the SGNA (Subjective Global Nutritional Assessment), PYMS (Pediatric Yorkhill Malnutrition Score), STAMP (Screening Tool for the Assessment of Malnutrition in Paediatrics), and STRONGkids (Screening Tool for Risk of Nutritional Status and Growth). This review included recently published reports supporting the validation and implementation of NSTs in pediatric populations. A child's nutritional status during hospitalization is of great importance for their recovery, while the implementation of screening tools enhances their clinical outcomes. Current tools have varying sensitivities and specificities, and no single tool can be recommended for all groups of hospitalized children. A combination of tools or adaptation of existing tools with validation in different contexts might be ideal. Further studies are required to develop more robust and comprehensive screening tools.
- Open Access
- 15 February 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (2) , 106-114
Promising role of voxelotor in managing sickle cell disease in children: a narrative review
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia and intermittent vasoocclusive crises. To date, 4 disease-modifying drugs have been approved for the treatment of SCD: hydroxyurea (an S-phase inhibitor), L-glutamine (an amino acid), crizanlizumab (a P-selectin inhibitor), and voxelotor (a hemoglobin S polymerization inhibitor). Preclinical studies suggested that voxelotor effectively treats SCD and sickle cell anemia (SCA). In a phase III trial, voxelotor-treated patients showed significantly elevated hemoglobin levels (>1 g/dL from baseline) compared to placebo-treated patients. The group that received voxelotor also showed a greater decrease in hemolytic markers but a comparable incidence of side effects. Six ongoing clinical trials also sought to ascertain the effectiveness and safety of high-dose voxelotor when administered to children younger than 12 years. Studies assessing their long-term efficacy and safety are needed to fully understand the role of voxelotor in treating SCD/SCA. In this review, we discuss the mechanisms, trials to date, and future treatment directions of voxelotor.
- 15 February 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (2) , 106-114
Open AccessPromising role of voxelotor in managing sickle cell disease in children: a narrative review
Sickle cell disease (SCD) is characterized by chronic hemolytic anemia and intermittent vasoocclusive crises. To date, 4 disease-modifying drugs have been approved for the treatment of SCD: hydroxyurea (an S-phase inhibitor), L-glutamine (an amino acid), crizanlizumab (a P-selectin inhibitor), and voxelotor (a hemoglobin S polymerization inhibitor). Preclinical studies suggested that voxelotor effectively treats SCD and sickle cell anemia (SCA). In a phase III trial, voxelotor-treated patients showed significantly elevated hemoglobin levels (>1 g/dL from baseline) compared to placebo-treated patients. The group that received voxelotor also showed a greater decrease in hemolytic markers but a comparable incidence of side effects. Six ongoing clinical trials also sought to ascertain the effectiveness and safety of high-dose voxelotor when administered to children younger than 12 years. Studies assessing their long-term efficacy and safety are needed to fully understand the role of voxelotor in treating SCD/SCA. In this review, we discuss the mechanisms, trials to date, and future treatment directions of voxelotor.